Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 11/20 | 0.49 |
| ▸ | GRM5 | P41594 | 10/20 | 0.49 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
| ▸ | JAK1 | P23458 | 1/20 | 0.45 |
| ▸ | HTR6 | P50406 | 1/20 | 0.43 |
| ▸ | ATR | Q13535 | 2/20 | 0.43 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12538003 | 0.86 | JAK1 (0.44) | GRM1GRM5PDK4NAMPTJAK1 | |
| SCHEMBL4011645 | 0.78 | GRM1 (0.51) | GRM1GRM5PDK4NAMPTTNK2 | |
| SCHEMBL12537915 | 0.76 | GRM1 (0.53) | GRM1GRM5PDK4NAMPTHTR6 | |
| SCHEMBL31701242 | 0.76 | GRM1 (0.55) | GRM1GRM5PDK4NAMPTHTR6 | |
| SCHEMBL64945 | 0.76 | GRM1 (0.55) | GRM1GRM5PDK4NAMPTHTR6 | |
| SCHEMBL24880472 | 0.76 | GRM1 (0.61) | GRM1GRM5PDK4NAMPTJAK1 | |
| SCHEMBL30849191 | 0.76 | PDK4 (0.53) | GRM1GRM5PDK4NAMPTJAK1 | |
| SCHEMBL15756313 | 0.75 | GRM1 (0.52) | GRM1GRM5PDK4NAMPTJAK1 | |
| SCHEMBL31612894 | 0.75 | NAMPT (0.53) | GRM1GRM5PDK4NAMPTATR | |
| SCHEMBL1698955 | 0.75 | NAMPT (0.53) | GRM1GRM5PDK4NAMPTATR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170152263-A1 | Substituted Indazole Compounds as IRAK4 Inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2017-06-01 | — | — | US | disclosed |
| US-20170152263-A1 | Substituted Indazole Compounds as IRAK4 Inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2017-06-01 | — | — | US | disclosed |
| US-20170152263-A1 | Substituted Indazole Compounds as IRAK4 Inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2017-06-01 | — | — | US | disclosed |
| EP-3157521-A1 | SUBSTITUTED INDAZOLE COMPOUNDS AS IRAK4 INHIBITORS | Aurigene Discovery Technologies Limited (IN) | 2017-04-26 | — | — | EP | disclosed |
| WO-2015193846-A1 | SUBSTITUTED INDAZOLE COMPOUNDS AS IRAK4 INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2015-12-23 | — | — | WO | disclosed |
| WO-2015193846-A1 | SUBSTITUTED INDAZOLE COMPOUNDS AS IRAK4 INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2015-12-23 | — | — | WO | disclosed |
| WO-2010014257-A2 | TETRAHYDROPYRIDINYL AND DIHYDROPYRROLYL COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. (US) | 2010-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170152263-A1 | Substituted Indazole Compounds as IRAK4 Inhibitors | IRAK4, IRAK3, IRAK2 | GRM1 2223/4885GRM5 2075/4885PDK4 897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.